Baker Brothers Life Sciences Plans $291M Celcuity Share Sale on FDA Approval Day
CELC has more than doubled off its 52-week low of $13.365.
Summary
Baker Brothers Life Sciences, a former Celcuity affiliate, plans to sell $291 million in shares on the day the FDA approved the company's breast cancer drug, a move that could weigh on the stock after a major catalyst.
Key Events · Ownership and Investor Activity · CELC
-
Major Shareholder Plans $291M Sale
Baker Brothers Life Sciences, L.P., a former affiliate, filed a Form 144 to sell 2,838,632 shares of Celcuity common stock, with an approximate market value of $290,959,780 based on the filing date price.
-
Combined Sale Totals 3.1M Shares
An affiliated entity, 667, L.P., is separately selling 261,368 shares, bringing the total planned sale by Baker Brothers entities to 3,100,000 shares.
-
Sale Timed with FDA Approval
The Form 144 was filed on July 14, 2026, the same day the FDA approved Celcuity's gedatolisib for HR-positive, HER2-negative advanced breast cancer, a major positive catalyst for the company.
-
Shares Acquired in Open Market
The shares to be sold were acquired in open market purchases between December 13, 2024 and May 16, 2025, indicating a potential profit-taking motive following the stock's appreciation.
Analysis · CELC · Industrial Applications And Services
On the very day the FDA approved Celcuity's breast cancer drug gedatolisib, former affiliate Baker Brothers Life Sciences filed to sell 2.84 million shares worth approximately $291 million. An affiliated entity, 667, L.P., is separately selling 261,368 shares, bringing the combined planned sale to 3.1 million shares. This represents a significant distribution by a knowledgeable investor, potentially signaling a view that the stock is fully valued after the approval catalyst. The sale is large enough to create substantial selling pressure, especially given the stock's recent volatility following mixed reactions to trial data.
At the time of this filing, CELC was trading at $103.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.37 to $151.02. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.